Ospemifene for vulvar and vaginal atrophy: an overview

Palacios, Santiago

doi:10.7573/dic.2020-3-2

Cited by 11 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TTPs have also been investigated for use in TESD and loss of libido after SSRIs/SNRIs with promising results [ 188 ]. The selective estrogen receptor modulator (SERM) ospemifene, intended for dyspareunia in postmenopausal women with VVA, is well tolerated and appears to result in significant improvement of every sexual function domain after 12 weeks of use [ 189 ].…”

Section: Introductionmentioning

confidence: 99%

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Chou

Kiebalo

Jagiello

et al. 2021

Life

View full text Add to dashboard Cite

Patient survival continues to increase with the growing quality of dialysis and management of chronic kidney disease (CKD). As such, chronic therapy must include considerations of quality of life (QOL), and this includes the disproportionate prevalence of sexual dysfunction (SD) in this patient population. This review aims to describe the pathophysiological and the psychosocial causes of SD with regard to renal replacement therapy, particularly hemo- and peritoneal dialysis. The differences in its manifestation in men and women are compared, including hormonal imbalances—and therefore fertility, libido, and sexual satisfaction—the experience of depression and anxiety, and QOL. The impact of comorbidities and the iatrogenic causes of SD are described. This review also presents validated scales for screening and diagnosis of SD in CKD patients and outlines novel therapies and strategies for the effective management of SD. Increased prevalence of CKD invariably increases the number of patients with SD, and it is crucial for health care professional teams to become familiar with the clinical tools used to manage this sensitive and under-quantified field. As a known predictor of QOL, sexual function should become a point of focus in the pursuit of patient-centered care, particularly as we seek to achieve as “normal” a life as possible for individuals who receive dialysis.

show abstract

Section: Introductionmentioning

confidence: 99%

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Chou

Kiebalo

Jagiello

et al. 2021

Life

View full text Add to dashboard Cite

show abstract

“…Ospemifene is said to exert a positive effect on the vaginal epithelium and, at the same time, not affecting other estrogen-dependent organs such as the breast and endometrium. Palacios S et al conducted a meta-analysis on this topic in 2020 with a total of 2086 participants, which were followed up to 52 weeks, and the result confirmed ospemifene to a good choice for treating vulvovaginal atrophy (VVA) as well as having protective effects on bone health [15].…”

Section: Ospemifene Usementioning

confidence: 96%

Fractional Carbon Dioxide Laser Therapy Compared to Ospemifene in the Treatment of Vaginal Atrophy in Menopause.

Udekwe¹

2022

Journal For International Medical Graduates

View full text Add to dashboard Cite

During the menopausal transition, women often experience an array of symptoms, including vaginal dryness, itching, pain, burning, decreased sexual desire, and inadequate lubrication, which are all due to hormonal changes called hypoestrogenism. Hypoestrogenism simply means a low level of estrogen which turn leads to a constellation of symptoms including hot flashes, urinary tract infections, decreased bone density and sleep disturbances. Some women find these symptoms embarrassing not to seek help, while some take it as a natural process of aging. Although various researchers have established different treatments in the past, such as lubricants and moisturizers, newer therapies such as fractional carbon dioxide (CO2) laser therapy and a selective estrogen receptor modulator ospemifene are currently being used and yet still researched. To highlight the lack of research on this topic, our article search involving only the PubMed database yielded 175 articles initially, but after exclusion and inclusion criteria, we were left with only 32 studies directly related to our research topic. Our study included English articles, full-text articles, articles on human studies, and articles from 2005- 2020. We excluded all studies prior to 2005, animal studies, pediatrics study, and only abstract study. All articles were chosen without limitation to the type of study. Our review suggests that patients often present with various symptoms and severity based on histology, mechanisms, and clinical findings. Therefore, treatment should be personalized. Our study aimed to further understand a better treatment option for vulvovaginal atrophy (VVA) in postmenopausal women, knowing that menopause is an inevitable stage of a woman's life.

show abstract

“…It is indicated for the treatment of GSM moderate to severe associated symptoms in healthy post-menopausal women [ 70 ]. Since its antiestrogenic or neutral effects on the breast tissue, ospemifene might be an option for BC survivors who completed endocrine adjuvant therapy but is contraindicated for patients still on treatment [ 23 , 70 , 71 ]. This implies that, during the 5–10 years of adjuvant therapy, patients with BC or hormone-dependent tumors can safely resort to non-hormonal treatments only [ 55 ].…”

Section: Gsm Managementmentioning

confidence: 99%

Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?

et al. 2022

View full text Add to dashboard Cite

Genitourinary syndrome of menopause (GSM) is a chronic condition affecting a large number of women, with a major impact on their urogenital health and sexual function. It occurs at midlife because estrogen levels decline with menopause enhancing aging-related changes of the functional anatomy of the urogenital system. Unfortunately, GSM may occur early in the lifespan of women or be exacerbated following anticancer treatments, such as chemotherapy, ionizing radiation, or surgical removal of reproductive organs. Symptoms of GSM are often under-reported by women, under-estimated and under-diagnosed by health care providers (HCPs), and subsequently under-treated, despite their profound negative impact on the quality of life. The mainstay of vaginal treatments is local estrogen therapy (LET) ensuring an effective management of moderate to severe symptomatic GSM. However, LET is generally contraindicated in women with a history of hormone receptor positive cancer, due to the fear of increased recurrence or possible interference with endocrine adjuvant therapies. Among non-hormonal treatments, hyaluronic acid-based moisturizers have shown promising clinical results both in healthy women and in cancer patients or survivors. Its strong water-binding properties provide lubricating and moisturizing effects, which contribute to maintaining a proper level of hydration and viscoelasticity in several body parts, including the urinary tract and genital tissues. Hyaluronic acid-based moisturizers are effective, safe, and well tolerated; therefore, they may represent a valid option for the early management of GSM-associated symptoms in every woman with a history of cancer who is unable or unwilling to undergo hormone-based therapies. Hence, the aim of this review was to provide an overview of GSM etiology and treatment in women with natural or iatrogenic menopause, with a focus on the use of hyaluronic acid as a prophylactic treatment in the context of an integrated management protocol for cancer patients.

show abstract

Ospemifene for vulvar and vaginal atrophy: an overview

Cited by 11 publications

References 32 publications

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Fractional Carbon Dioxide Laser Therapy Compared to Ospemifene in the Treatment of Vaginal Atrophy in Menopause.

Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?

Contact Info

Product

Resources

About